The estimated Net Worth of Aimee S Weisner is at least $7.16 Million dollars as of 8 August 2024. Ms. Weisner owns over 25,000 units of Glaukos stock worth over $6,917,435 and over the last 14 years she sold GKOS stock worth over $0. In addition, she makes $238,256 as Independent Director at Glaukos.
Sign up
Ms. Weisner GKOS stock SEC Form 4 insiders trading
Aimee has made over 8 trades of the Glaukos stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 25,000 units of GKOS stock worth $800,000 on 8 August 2024.
The largest trade she's ever made was exercising 25,000 units of Glaukos stock on 8 August 2024 worth over $800,000. On average, Aimee trades about 1,342 units every 86 days since 2011. As of 8 August 2024 she still owns at least 55,119 units of Glaukos stock.
You can see the complete history of Ms. Weisner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Aimee Weisner biography
Aimee S. Weisner J.D. serves as Independent Director of the Company. Ms. Weisner has been corporate vice president, general counsel of Edwards Lifesciences Corporation since January 2011. From 2009 to 2010, she was engaged in private practice and served as legal advisor to public pharmaceutical and medical device companies located in Southern California. Prior to this, from 2002 to 2009, Ms. Weisner served in a number of positions at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), including executive vice president, administration and secretary. From 1998 to 2002, Ms. Weisner served in a number of positions at Allergan, Inc., including vice president, assistant general counsel and assistant secretary. Ms. Weisner holds a B.A. from California State University, Fullerton, a J.D. from Loyola Law School, Los Angeles, and began her legal career as an associate at the law firm of O’Melveny & Myers LLP.
What is the salary of Aimee Weisner?
As the Independent Director of Glaukos, the total compensation of Aimee Weisner at Glaukos is $238,256. There are 9 executives at Glaukos getting paid more, with Thomas Burns having the highest compensation of $5,716,560.
How old is Aimee Weisner?
Aimee Weisner is 51, she's been the Independent Director of Glaukos since 2014. There are 8 older and 3 younger executives at Glaukos. The oldest executive at Glaukos Corporation is William Link, 74, who is the Independent Chairman of the Board.
What's Aimee Weisner's mailing address?
Aimee's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Insiders trading at Glaukos
Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman, and Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.
What does Glaukos do?
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
What does Glaukos's logo look like?
Complete history of Ms. Weisner stock trades at Staar Surgical Co, Edwards Lifesciences Corp, Glaukos, and Oyster Point Pharma Inc
Glaukos executives and stock owners
Glaukos executives and other stock owners filed with the SEC include:
-
Thomas Burns,
President, Chief Executive Officer, Director -
Chris Calcaterra,
Chief Operating Officer -
Joseph Gilliam,
Chief Financial Officer, Senior Vice President - Corporate Development -
Thomas William Burns,
Chairman, CEO & Pres -
Joseph E. Gilliam,
CFO & Sr. VP of Corp. Devel. -
Chris M. Calcaterra,
Chief Operating Officer -
William Link,
Independent Chairman of the Board -
Marc Stapley,
Independent Director -
Mark Foley,
Independent Director -
Aimee Weisner,
Independent Director -
David Hoffmeister,
Independent Director -
Gilbert Kliman,
Director -
L. Jay Katz,
Chief Medical Officer -
L. Jay Katz M.D., FACS,
Chief Medical Officer -
David S. Haffner,
Sr. VP of New Technologies -
Michele M. Allegretto,
Sr. VP of HR -
Diana A. Scherer,
VP of Compliance & Deputy Gen. Counsel -
Diane W. Biagianti,
Sr. VP & Gen. Counsel -
Christopher William Lewis,
Director of Investor Relations, Corp. Strategy & Devel. -
Dr. Mory Gharib Ph.D.,
Co-Founder -
Advisors Llc Orbi Med Capit...,
-
Advisors Llc Orbi Med Capit...,
-
Equity Partners Iv Lp Montr...,
-
Jonathan Silverstein,
Director -
Richard L Harrison,
Treasurer, CFO & Secretary -
Ventures I Llclubash Barbar...,
-
Ventures I Llcversant Ventu...,
-
Partners Iv Lpblair James C...,
-
Iv Associates Lpblair James...,
-
Viii Associates, L.P.Blair ...,
-
Management Partners Ix, Llc...,
-
Healthcare V, Lpfhm V, Llc ...,
-
Ventures I Llcversant Ventu...,
-
Robert J More,
Director -
Paul S Madera,
Director -
Olav Bergheim,
Director -
Ventures I Llcversant Ventu...,
-
Partners Viii, L.P.Blair Ja...,
-
Capital Associates Iii L.L....,
-
Alex R. Thurman,
SVP & CHIEF FINANCIAL OFFICER -
Tomas Navratil,
CHIEF DEVELOPMENT OFFICER -
Leana Wen,
-
Denice Torres,